Leerink analyst David Risinger upgraded Johnson & Johnson to Outperform from Market Perform with a $265 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- FDA Commissioner Marty Makary resigns
- Trump confirms Kyle Diamantas to be acting head of FDA
- Trump Trade: Trump to suspend tariff-rate quotas on beef imports
- Johnson & Johnson announces global launch of Shockwave C2 Aero catheter
- Kennedy driving vast vaccine inquiry despite toned-down criticism, NYT says